|
Patent landscape, scope, and claims summary: |
US Patent 8,476,239 Claim-By-Claim Analysis and US Patent Landscape for CTLA4Ig Subcutaneous Stable Formulations
US Patent 8,476,239 is directed to a high-concentration, sugar-stabilized, subcutaneous formulation of CTLA4Ig (abatacept-like biologic) with defined pH, viscosity, sugar:protein weight ratio, and optional buffer/surfactant. The independent claim 1 ties together five technical constraints that are likely engineered around stress-stability, syringeability, and freeze-thaw/osmotic behavior for SC delivery: (i) sugar selection and minimum sugar:protein ratio, (ii) pH 6 to 8, (iii) viscosity 9 to 20 cps, (iv) ≥100 mg/mL CTLA4Ig, and (v) pharmaceutically acceptable aqueous carrier.
Below is a critical claim construction and enforceability assessment against the typical design-around space for SC biologic formulations, followed by the US competitive patent landscape that most commonly overlaps this type of formulation IP: abatacept (Orencia) formulation patents, generic/biosimilar fill-finish and stabilization patents, and composition-of-matter adjacent sequence/formulation claims for CTLA4Ig variants.
What does US 8,476,239 claim 1 cover, and how narrow is it for CTLA4Ig subcutaneous formulations?
Featured snippet answer: Claim 1 requires a stable SC formulation with ≥100 mg/mL CTLA4Ig, specific sugars (sucrose/lactose/maltose/mannitol/trehalose), pH 6 to 8, viscosity 9–20 cps, and sugar:protein ≥1.1:1.
Key claim 1 limitations that drive infringement risk
Claim 1 combines multiple parameter ranges that must all be met simultaneously:
-
Target protein concentration
- “At least 100 mg/mL CTLA4Ig molecule.”
- Practical effect: pushes coverage toward high-strength SC dosing solutions used for convenient administration volume. Lower-concentration formulations are less likely to infringe.
-
Sugar identity and minimum loading
- Sugar is limited to sucrose, lactose, maltose, mannitol, trehalose, or mixtures.
- Enforces a minimum stabilization excipient set rather than “any sugar.”
- Sugar:protein weight ratio ≥1.1:1 is a hard quantitative gate.
- This ratio is often the easiest parameter for generic/biosimilar teams to tune, but it also becomes a precise “design-around knob.”
-
pH range
- pH must be 6 to 8.
- Many protein formulations also sit around pH 6–7. The range is not highly distinctive, but coupled with viscosity and sugar:protein ratio it becomes more restrictive.
-
Viscosity range
- Viscosity must be 9 to 20 cps.
- This parameter is frequently measured, but measurement methods (temperature, shear, instrument) can vary. Even so, the claim reads as a direct numeric requirement that can be tested in litigation.
-
Subcutaneous compatibility
- The claim says “suitable for subcutaneous administration.”
- This can be argued as inherent if all other constraints match SC-ready solutions. In practice, parties often treat this as satisfied if it is a SC drug product rather than an IV-only formulation.
Critical enforceability notes
- Multi-parameter coupling improves non-infringement leverage. A competitor can attempt to hit pH and sugar identity but miss viscosity or sugar:protein ratio.
- Measurement disputes are likely in any validity/infringement dispute involving viscosity and pH at specification conditions.
- Claim breadth is constrained by CTLA4Ig being the protein species; if a competitor uses a different CTLA4Ig sequence/variant not within the defined molecule scope, claim 1 may not be directly applicable (though dependent claims pick up explicit sequences).
How do dependent claims 2, 5, and 14–15 narrow sugar selection and loading in US 8,476,239?
Claim 2: sugar subset
- Claim 2 limits claim 1 to sucrose, mannitol, or trehalose.
- This trims the claim’s excipient universe from five sugars to three.
Claim 5: sucrose-specific
- Claim 5 requires sugar = sucrose.
- Claim 14 adds a further quantitative window:
- sucrose:protein = 1.3:1 to 5:1
- Claim 15 specifies a point value:
Critical reading
- Claims 14–15 are highly specific. These are typically the claims that become the primary infringement targets for any product whose formulation recipe was copied or closely followed.
- A design-around strategy commonly targets:
- the sucrose:protein ratio outside the narrow subrange (eg <1.3:1 or >5:1), or
- the viscosity target outside 9–20 cps.
What do claims 3, 6, and 8 add about buffer presence and strength?
- Claim 3: formulation further comprising a pharmaceutically acceptable buffer.
- Claim 6: buffer in the sequence-specific dependent formulation.
- Claim 8: buffer amount is at least 10 mM phosphate buffer.
Critical reading
- Buffer presence is routine in biologic formulations, but the ≥10 mM phosphate limitation is measurable and can narrow design-around.
- A competitor could attempt to use non-phosphate buffers or keep phosphate below 10 mM while still keeping pH 6–8 via other buffer systems.
How do claims 7, 9–11 define a specific SC bottle-fillable recipe (125 mg/mL, sucrose ~170 mg/mL)?
Claim 7: a practical composition-with-dosing-style recitation
Claim 7 hard-codes a formulation recipe, including:
- CTLA4Ig sequence defined in claim 4 (SEQ ID NO:2 region constraints)
- ~125 mg/mL CTLA4Ig
- ~170 mg/mL sucrose
- at least one buffering agent
- sterile water for injection
- optional surfactant
Claims 9, 10, 11
- Claim 9: surfactant = Poloxamer 188 ~8 mg/mL
- Claim 10: pH 6 to 8
- Claim 11: stable when stored at 2 to 8°C for at least 12 months
Critical enforceability notes
- Claim 7 resembles a “label-like” formulation with near manufacturing targets.
- Stability (12 months at 2–8°C) can become an enforceability hinge:
- plaintiffs typically use accelerated or real-time stability data,
- defendants may run alternative stability studies or argue formulation/conditions differences.
- Optional surfactant creates ambiguity:
- If Poloxamer 188 is optional in claim 7, infringement may still occur without it, as long as the rest is met.
- Claim 9 creates a specific infringement path if Poloxamer 188 is used at the recited level.
How do claims 4 and 7 tie the formulation to a specific CTLA4Ig sequence region?
Claim 4 requires:
- CTLA4Ig having amino acid sequence shown in SEQ ID NO:2
- “starting at methionine at position 27 or alanine at position 26”
- “ending at lysine at position 383 or glycine at position 382”
Critical reading
- This is not a full-length “entire sequence” statement; it is a defined start/end boundary in the sequence context.
- For a competitor, the sequence-driven dependency can create non-infringement if:
- they use a CTLA4Ig molecule with differing N- or C-terminal processing relative to the stated boundaries, or
- their construct maps to different effective residues after processing.
- In practice, for marketed abatacept-like molecules, the exact mature chain ends are usually known, but biosimilar developers often match processing and sequence precisely for comparability.
What does claim 12–13 cover on the device and instructions side, and does it extend IP beyond formulation?
- Claim 12: article of manufacture comprising
- container holding formulation of claim 1, 4, or 7, and
- instructions for administering SC to a subject.
- Claim 13: container is a vial or syringe.
Critical reading
- These are relatively standard “kit-like” packaging claims.
- They often add leverage in marketing and product distribution, not just manufacturing.
- A competitor who launches a product with the same formulation (or infringing formulation) will generally satisfy the “container + instructions” element if they package for SC use in vials/syringes and include administration instructions.
What does this patent likely correspond to commercially: abatacept (Orencia) and CTLA4Ig SC formulation design?
CTLA4Ig is the biologic underlying abatacept. US formulation and device packaging patents commonly cluster around:
- high concentration for SC administration,
- sucrose or other sugar stabilizers,
- controlled pH and viscosity for needle/syringe delivery,
- phosphate buffering systems,
- optional surfactants such as polysorbates or poloxamers,
- refrigerated stability specifications.
US 8,476,239’s combination of high protein concentration + sucrose and specific viscosity is consistent with formulation IP that aims to protect practical manufacturability and dosing convenience, not just molecular identity.
Which patent clusters are most likely to overlap US 8,476,239 in the US (Orange Book listing and biologics patent universe)?
Because US 8,476,239 is a formulation patent for CTLA4Ig, the most relevant overlap zones in the US are:
1) Abatacept formulation patents (sucrose, pH, viscosity, buffer, surfactant)
Expect adjacent protection around:
- sugar-based stabilization formulations,
- buffer system selection (phosphate concentration),
- viscosity modifiers and target viscosity windows,
- surfactant choice and concentration.
2) CTLA4Ig sequence/construct patents and processing endpoints
Even though this patent is formulation-focused, it includes sequence boundary limitations in dependent claims. That places it within the broader biologic estate covering the CTLA4Ig molecule construct used for abatacept-like products.
3) Method-of-use vs. formulation boundaries
CTLA4Ig is an approved biologic; “method-of-use” patents can exist, but US 8,476,239 is not primarily a therapeutic method claim. It is composition/formulation and article-of-manufacture.
4) Fill-finish and manufacturability patents
The viscosity/pH/stability requirements are typically enforced in product-specific claims, which can overlap with manufacturing process IP in some estates.
When does exclusivity end for CTLA4Ig in the US, and how does that interact with formulation patents like US 8,476,239?
Featured snippet answer: Regulatory exclusivity (biologics exclusivity) and patent expiration work independently; formulation patents can extend market barriers well after marketing exclusivity ends.
Regulatory exclusivity framework (interaction with patent expiry)
- For biologics, the FDA approval date triggers exclusivity under the BLA framework (the Biologics Price Competition and Innovation Act structure).
- Even after exclusivity ends, a biosimilar or interchangeable candidate must navigate:
- remaining patents listed in the relevant FDA patent listing,
- FDA litigation stays (if biosimilar engages the patent dispute workflow),
- settlement agreements that can delay launch.
Practical implication for US 8,476,239
- If US 8,476,239 is listed for the CTLA4Ig reference product in the relevant FDA patent listing, it becomes part of the “patent wall” impacting biosimilar launch timing.
- If it is not listed, the practical effect is reduced but enforcement through infringement litigation remains possible if the patent is otherwise enforceable.
What is the most likely Paragraph IV / patent challenge posture for CTLA4Ig formulation patents?
Featured snippet answer: For a biosimilar pathway, challenges are typically managed through the BPCIA patent dispute framework, not classic Hatch-Waxman Paragraph IV filings for small molecules. The functional goal is the same: contest patent validity and/or non-infringement to enable earlier launch.
Where a formulation patent like US 8,476,239 is attacked
- Non-infringement: new formulation does not meet one or more numeric constraints (sugar:protein ratio, viscosity, pH).
- Invalidity: obviousness-type attacks based on prior sugar-stabilized biologic formulations with similar parameter ranges; anticipation attacks if the prior art discloses the same recipe and ranges.
- Enablement/description: if the patent spec does not support claimed viscosity/sugar ratio boundaries across the breadth.
How strong is the patent estate if US 8,476,239 is challenged: stability + numeric formulation claims vs typical prior art?
Strength levers
- Numeric ranges (pH 6–8, viscosity 9–20 cps) can support novelty if prior art teaches different parameter windows.
- Sugar:protein ratio thresholds can be distinctive if the prior art fails to specify ratios or teaches away by using much lower sugar loads.
- Specific recipe claims (125 mg/mL CTLA4Ig and ~170 mg/mL sucrose, optional Poloxamer 188 ~8 mg/mL) are closer to “product-as-made” and may be harder to find in generic/formulation prior art unless the competitor reused the same design.
Weakness levers
- If the priority art includes a CTLA4Ig formulation with:
- similar sugar types and loadings,
- similar pH windows,
- similar viscosity targets,
then obviousness can still succeed even if exact parameter values differ slightly.
- Viscosity is often sensitive to temperature, shear, and measurement method. If prior art includes viscosity numbers obtained under different conditions, defendants can argue lack of clear overlap.
How does US 8,476,239 compare with typical sugar-stabilized monoclonal antibody or Fc-fusion SC formulation patents?
Featured snippet answer: The claim differentiator is the combination of high-concentration CTLA4Ig, strict sucrose/mannitol/trehalose (and other sugars) selection, sugar:protein ≥1.1:1, plus viscosity 9–20 cps, and pH 6–8. Many prior art patents protect sugars and buffers but not this full numeric coupling.
Design-around space
Competitors generally try to move at least one of these parameters:
- Protein concentration: use lower mg/mL and adjust dosing volume.
- Sugar type: use non-listed excipients or a sugar mixture excluding the claimed sugars.
- Sugar:protein ratio: move outside ≥1.1:1 or outside 1.3:1 to 5:1.
- Viscosity: adjust formulation composition to exceed 20 cps (more gel-like) or drop below 9 cps (more dilute).
- pH: move outside 6–8 while keeping acceptable stability (eg pH 5.5–6 or >8, depending on protein).
- Buffer system: use buffers other than phosphate or keep phosphate under 10 mM where that dependent claim matters.
- Surfactant: omit the recited Poloxamer 188 level if targeting dependent claim 9.
What litigation events or settlements typically shape launch risk for CTLA4Ig biosimilars against formulation patents?
For biologics with formulation patents in the asserted estate, launch timing is often shaped by:
- whether disputes resolve early with a settlement,
- whether courts issue claim construction that changes the “numeric gate” for viscosity/sugar ratio,
- whether stability and test-condition arguments become decisive.
This patent’s numeric limitations make it a candidate for:
- expert-driven non-infringement (do the competitor products hit all ranges?),
- validity attacks focusing on whether prior art formulation recipes inherently satisfy ranges.
Key Takeaways
- US 8,476,239 protects a specific CTLA4Ig SC formulation defined by protein concentration (≥100 mg/mL), sugar identity, sugar:protein ratio (≥1.1:1), pH (6–8), and viscosity (9–20 cps).
- The most enforceable hooks are typically the numeric gates and the sucrose-specific loading claims (notably 1.3:1 to 5:1 and 1.4:1).
- Dependent claims add protectable specificity through:
- sequence boundary constraints (SEQ ID NO:2 endpoints),
- buffer presence, including ≥10 mM phosphate,
- Poloxamer 188 ~8 mg/mL,
- 12-month stability at 2–8°C.
- Design-around risk centers on missing at least one numeric limitation, especially viscosity and sugar:protein ratio.
- In the US biologics competitive landscape, such patents usually operate as launch barriers when listed, and as infringement targets when not listed, depending on enforcement posture and evidence of product matching.
FAQs
- Can a biosimilar avoid US 8,476,239 by changing only sucrose:protein ratio while keeping pH and viscosity the same?
- Does omitting Poloxamer 188 prevent infringement of claim 7 or only claim 9?
- How do pH measurement conditions affect infringement arguments for the 6–8 range?
- What CTLA4Ig sequence endpoint changes are most likely to defeat dependent claim 4 coverage?
- If a competitor uses non-phosphate buffers, can it avoid claim 8 while still meeting overall pH 6–8?
References
- US Patent 8,476,239.
More… ↓
⤷ Start Trial
|
